Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609131 | 0.76 | — | — | |
| SCHEMBL1608120 | 0.76 | — | — | |
| SCHEMBL232762 | 0.76 | — | — | |
| SCHEMBL2199293 | 0.72 | — | — | |
| SCHEMBL7505546 | 0.71 | — | — | |
| SCHEMBL523425 | 0.71 | — | — | |
| SCHEMBL7511231 | 0.71 | — | — | |
| SCHEMBL1861312 | 0.71 | — | — | |
| SCHEMBL271888 | 0.71 | — | — | |
| SCHEMBL2475883 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-7351720-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-4447454-A | Analgetic compounds, compositions and process of treatment | THE UPJOHN COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4122264-A | Pyridine containing morpholines | THE UPJOHN COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4115396-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4113866-A | ANALGETIC COMPOUNDS, COMPOSITIONS AND PROCESS OF TREATMENT | THE UPJOHN COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
| US-4089672-A | HERBICIDES | THE UPJOHN COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4084955-A | 1-CARBOXYALKYL-DI- AND TRIHALOPYRAZOLES, HERBICIDES | THE UPJOHN COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4067874-A | Novel pyridine 1-oxides | THE UPJOHN COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3995035-A | 6-Amino-2-lower-alkyl-4-nitropyridine N-oxide compositions and coccidiostat process | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ACKR3, CCR7, CCR2 | NPC1 505/4885RAB9A 785/4885SMN1; SMN2 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.